Loading...
XPAR
BIM
Market cap9.77bUSD
Sep 17, Last price  
72.10EUR
1D
-0.48%
1Q
4.49%
Jan 2017
52.43%
IPO
621.00%
Name

Biomerieux SA

Chart & performance

D1W1MN
XPAR:BIM chart
P/E
21.40
P/S
2.09
EPS
3.37
Div yield, %
1.25%
Shrs. gr., 5y
0.06%
Rev. gr., 5y
5.47%
Revenues
4.07b
+2.26%
1,036,900,0001,062,800,0001,110,500,0001,223,400,0001,357,000,0001,427,200,0001,569,800,0001,587,900,0001,698,400,0001,964,600,0002,103,200,0002,288,200,0002,421,300,0002,674,800,0003,118,200,0003,376,200,0003,589,100,0003,674,700,0003,979,900,0004,069,800,000
Net income
398m
-8.03%
105,300,00098,100,000130,000,000148,200,000160,000,000158,200,000134,400,000164,300,000134,900,000110,500,000179,100,000238,100,000256,600,000272,800,000404,400,000601,100,000452,400,000357,600,000432,200,000397,500,000
CFO
788m
+18.13%
124,600,000188,700,000197,900,000188,600,000199,000,000216,600,000258,500,000240,500,000298,300,000310,000,000335,600,000341,300,000399,800,000407,900,000582,800,000824,700,000475,100,000445,400,000667,300,000788,300,000
Dividend
Jun 09, 20260.98 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.

Related entities

Subsidiaries (10)
BIOMERIEUX ASIA PACIFIC PTE. LTD.
bioMerieux Benelux
Biomerieux China Limited
BIOMERIEUX CZ S.R.O.
BIOMERIEUX ITALIA SPA
BIOMERIEUX MEXICO SA DE CV
bioMerieux Sweden AB
BIOMERIEUX, INC.
BTF PTY. LIMITED
BIOFIRE DIAGNOSTICS, LLC

Key people

Pierre Boulud
Corporate Vice-President, Asia-Pacific Region, Industrial Unit, Investments and Strategic Planning, Member of the Executive Board · since 2017
Nicolas Cartier
Corporate Vice President Industrial Applications unit, Member of the Executive Board · since 2014
Frederic Beseme
CSR Manager, Director · since 2018
Guillaume Bouhours
Executive Vice President Purchasing and Information Systems, Chief Financial Officer, Member of the Executive Board · since 2019
Francois Lacoste
Corporate Vice President, Clinical Unit, Member of the Executive Board · since 2014
Mark Miller
Chief Medical Officer, Member of the Executive Board · since 2014
Yasha Mitrotti
Corporate Vice President, Europe, Middle East, Africa Region & Worldwide Sales Performance, Member of the Executive Board · since 2015
Kirk Ririe
Chief Innovation Officer, Member of the Executive Board
Stefan Willemsen
Corporate Vice-President, Americas Region, Member of the Executive Board · since 2017
Michel Baguenault
Executive Vice-President, Member of the Executive Board, Secretary General, Head of Human Resources, Communications, Legal Affairs and Intellectual Property · since 2017
Marie-Helene Habert-Dassault
Independent Director · since 2012
Marie-Paule Kieny
Independent Director · since 2017
Fanny Letier
Independent Director · since 2017
URL
https://www.biomerieux.fr/
IPO date
Jun 07, 2004
Employees
12,557
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
376 CHEMIN DE L'ORME
MARCY-L'ETOILE, 69 69280
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT